AstraZeneca (NYSE:AZN) received a $38.00 price objective from analysts at BMO Capital Markets in a research note issued on Wednesday. The firm presently has a “buy” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 7.34% from the stock’s previous close.
Several other equities research analysts have also recently commented on the stock. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $30.00 to $39.00 in a research report on Friday, September 22nd. Citigroup raised shares of AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Leerink Swann boosted their price objective on shares of AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Finally, Liberum Capital lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and an average price target of $34.20.
Shares of AstraZeneca (NYSE AZN) opened at $35.40 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.92. The company has a market cap of $88,360.00, a PE ratio of 25.29, a price-to-earnings-growth ratio of 3.44 and a beta of 0.76.
Several institutional investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC increased its stake in shares of AstraZeneca by 4.7% during the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock worth $393,061,000 after purchasing an additional 519,717 shares during the last quarter. Wells Fargo & Company MN grew its stake in AstraZeneca by 7.6% in the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after buying an additional 310,389 shares during the last quarter. Ameriprise Financial Inc. grew its stake in AstraZeneca by 7.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after buying an additional 199,519 shares during the last quarter. Capital Bank & Trust Co grew its stake in AstraZeneca by 2.1% in the 3rd quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after buying an additional 57,353 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in AstraZeneca by 18.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock valued at $86,695,000 after buying an additional 395,699 shares during the last quarter. Institutional investors own 14.75% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2018/01/12/astrazeneca-azn-pt-set-at-38-00-by-bmo-capital-markets.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.